Contracts Finder

NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche

NHS England

Awarded
goods
SME-friendly
Framework agreement

This tender has closed

The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.

Key details

Contracting authority
NHS England
nhs
Region
RUNCORN
Sector
Healthcare & Medical
Contract value
£261,970,000ex VAT
Submissions closed
24 October 2022
Published
14 March 2023

Procurement

Contract period
1 March 2023 - 28 February 2025
2 years
Procedure type
Open procedure (above threshold)
CPV classifications
  • 33600000 Pharmaceutical products

What happened

NHS England awarded this contract to Roche Products Ltd | Sandoz Ltd | Teva UK Limited | Celltrion Healthcare United Kingdom Limited | Merck Sharpe & Dohme (UK) Limited | Chugai Pharma UK Ltd | Amgen Ltd | Janssen-Cilag Ltd | Accord-UK Ltd | Pfizer Ltd | Thornton and Ross Ltd | GlaxoSmithKline UK Limited | Abbvie Ltd | Aventis Pharma ltd t/a Sanofi | Ipsen | AstraZeneca | Pharmacosmos UK Ltd | Takeda UK Ltd | Merck Serono Limited | Organon Pharmaceuticals UK Ltd | Zentiva Pharma UK Ltd | Novo Nordisk | Merz | Eli Lilly & Company Ltd | Vifor Pharma UK Ltd | Sobi (Swedish Orphan Biovitrum Ltd) | Gedeon Richter UK Ltd | Almirall | UCB Pharma Ltd (primary) worth £261,970,000 on 8 Feb 2023. The contract runs until 28 Feb 2025.

Description

NHS Framework for North of England Branded Medicines - Tranche A and Annual Tranche.

Offer reference number: CM/PHR/20/5606

CM/PHR/20/5606/01 - NHS Framework for North of England Branded Medicines - Tranche A. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5606/02 - NHS Framework for North of England Branded Medicines - Annual Tranche. Period of framework: 1 March 2023 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/20/5606/03 - NHS National Framework Agreement for the supply of Risankizumab for South of England and London. Period of framework: 1 March 2023 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months

Awarded suppliers (29)

Suppliers
  • Roche Products Ltd
  • Sandoz Ltd
  • Teva UK Limited
  • Celltrion Healthcare United Kingdom Limited
  • Merck Sharpe & Dohme (UK) Limited
  • Chugai Pharma UK Ltd
  • Amgen Ltd
  • Janssen-Cilag Ltd
  • Accord-UK Ltd
  • Pfizer Ltd
  • Thornton and Ross Ltd
  • GlaxoSmithKline UK Limited
  • Abbvie Ltd
  • Aventis Pharma ltd t/a Sanofi
  • Ipsen
  • AstraZeneca
  • Pharmacosmos UK Ltd
  • Takeda UK Ltd
  • Merck Serono Limited
  • Organon Pharmaceuticals UK Ltd
  • Zentiva Pharma UK Ltd
  • Novo Nordisk
  • Merz
  • Eli Lilly & Company Ltd
  • Vifor Pharma UK Ltd
  • Sobi (Swedish Orphan Biovitrum Ltd)
  • Gedeon Richter UK Ltd
  • Almirall
  • UCB Pharma Ltd (primary)
Award value
£261,970,000
Award date
8 February 2023

Contact

Address
2nd Floor Rutland House, Runcorn, WA7 2ES
Contact name
Katie Noonan
Email
[email protected]

Identifiers

Buyer reference
CF-1314600D0O000000rwimUAA
Notice ID
132e813f-39e2-4dce-ae80-1778abe1fa51-624078
OCID
ocds-b5fd17-9ad5373a-6289-47c2-89c6-8c7250be3555

Explore related tenders

Other tenders from NHS England

View all →
Secondary Care Medicines Data Pre-Market Engagement£6,750,000
Quality Assurance & Improvement of Structured Learning Placement (SLP) Modules£98,000
Targeted Prostate Cancer Screening Programme - MRI Reporting Service
Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service
Strengthening Cultural Capability and Trauma Informed Care in Women’s Health£175,000

External ID: cf-ocds-b5fd17-9ad5373a-6289-47c2-89c6-8c7250be3555 • Added 4 October 2026